Xcout IntelCHARM Therapeutics Inc.
CHARM Therapeutics Inc. is a biopharmaceutical company utilizing proprietary technology platforms for drug discovery and therapeutic pipeline development.
Subscribe to see CHARM Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CHARM Therapeutics Inc. at a glance
CHARM Therapeutics Inc. is a biotechnology company headquartered in United Kingdom, founded in 2021. It has raised at least $149.7M across the 4 funding rounds on record. Its most recent funding round, Series B, raised $80M in September 2025. Xcout tracks 10 named people at CHARM Therapeutics Inc., including Gary D. Glick (Executive Chair).
CHARM Therapeutics Inc. leadership
- Gary D. GlickExecutive Chair
- David Bakerfounder
- Laksh Aithanifounder
- Gary GlickExecutive Officer
- Briggs MorrisonDirector
- Kim BlackwellDirector
4 more named people on record for CHARM Therapeutics Inc., with roles, board committees and tenure — see the full roster →
CHARM Therapeutics Inc. funding rounds
At least $149.7M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $80M | 7 named | |
| Series B | $20M | 6 named | |
| SEC Form D filing | $37M | — | |
| SEC Form D filing | $12.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
CHARM Therapeutics Inc. competitors
A few of CHARM Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Violet Therapeutics, Inc. is a therapeutics company headquartered in Cambridge, Massachusetts, utilizing novel proprietary platforms for drug development.
Exo Therapeutics is a small molecule drug discovery and development biotechnology company headquartered in Cambridge, Massachusetts. The company utilizes a pioneering proprietary technology platform to unlock and address notoriously intractable pharmaceutical and disease targets.
Sharp Therapeutics Corp. is a preclinical-stage biotechnology and drug discovery company that develops small molecule therapies to treat genetic diseases and hereditary disorders. The company combines high-speed experimentation and computational methods to advance its drug discovery platform.
Combined Therapeutics is a biotechnology company that develops next-generation mRNA vaccines and immunotherapies for infectious diseases and oncology. The company utilizes a proprietary mRNA platform featuring microRNA binding sequences to target therapeutic protein expression in specific tissues while protecting vital organs from off-target effects.
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Get CHARM Therapeutics Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CHARM Therapeutics Inc. in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access